Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
NCT04708314Phase 4Terminated
- Sponsor
- Rare Disease Research
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 4 trial of golodirsen in Duchenne muscular dystrophy (DMD), sponsored by Rare Disease Research. Started Oct 2020; status: terminated.
02
Drugs
golodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04708314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708314.